Erivedge Approval History

• FDA approved: Yes (First approved January 30th, 2012)
• Brand name: Erivedge
• Generic name: vismodegib
• Company: Genentech
• Treatment for: Basal Cell Carcinoma

Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell carcinoma (BCC).

Development History and FDA Approval Process for Erivedge

Date	Article
Jan 30, 2012	FDA Approves Erivedge for Basal Cell Carcinoma
Nov  9, 2011	FDA Accepts Genentech's New Drug Application For Vismodegib in Advanced Form of Skin Cancer
Sep 12, 2011	Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.